SCHEMBL302571

SCHEMBL302571

O=S(=O)(NC(F)(F)F)c1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.55
L3MBTL1 Q9Y468 1/20 0.55
CA1 P00915 1/20 0.52
CA2 P00918 1/20 0.52
MMP1 P03956 1/20 0.52
MMP2 P08253 1/20 0.52
MMP9 P14780 1/20 0.52
MMP8 P22894 1/20 0.52
MMP13 P45452 1/20 0.52
KMT2A Q03164 3/20 0.50
MEN1 O00255 2/20 0.50
KEAP1 Q14145 2/20 0.50
TSHR P16473 1/20 0.50
HTT P42858 1/20 0.50
IL1RN P18510 1/20 0.50
ERAP1 Q9NZ08 1/20 0.50
ALDH1A1 P00352 3/20 0.47
PKM P14618 2/20 0.47
PPARG P37231 1/20 0.46
NR1H3 Q13133 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL2640192 0.98 GAA (0.54) GAAL3MBTL1CA1CA2MMP1
Trifluoroacetic Acid SCHEMBL15918326 0.90 GAA (0.56) GAAL3MBTL1CA1CA2MMP1
Formic Acid SCHEMBL19617351 0.90 GAA (0.52) GAAL3MBTL1CA1CA2MMP1
SCHEMBL1068742 0.88 MMP1 (0.50) GAAL3MBTL1CA1CA2MMP1
Hydrochloric Acid SCHEMBL16015051 0.86 MMP1 (0.49) GAAL3MBTL1CA1CA2MMP1
SCHEMBL1069771 0.83 PTGES2 (0.50) GAAL3MBTL1CA1CA2MMP1
SCHEMBL1281419 0.79 GAA (0.50) GAAL3MBTL1CA1CA2MMP1
SCHEMBL797959 0.78 CA2 (0.55) GAACA1CA2MMP1MMP2
SCHEMBL12054697 0.78 CA1 (0.53) CA1CA2MMP1MMP2MMP9
SCHEMBL20395718 0.78 HTR6 (0.41) GAAL3MBTL1CA1CA2MMP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 664 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630529-B2 GCN2 modulator compounds Alesta Therapeutics BV (NL) 2026-05-19 US claimed
US-20260022096-A1 NOVEL SULFONAMIDES AND THEIR USE AS NEUROPROTECTIVE AND/OR NEURORESTORATIVE AGENTS GENECODE (EE) 2026-01-22 US claimed
US-12331026-B2 Sulfonamido derivatives as cyclin-dependent kinase 2 inhibitors NIKANG THERAPEUTICS, INC. (US) 2025-06-17 US claimed
CN-115117442-B Single ion gel polymer electrolyte, preparation and application thereof 华中科技大学 2024-10-22 CN claimed
US-20240262801-A1 COMPOUNDS HAVING 5-(2-FLUORO-6-HYDROXYPHENYL)-1,2,5-THIADIAZOLIDIN-3-ONE 1,1-DIOXIDE AS INHIBITORS OF PROTEIN KINASE PHOSPHATASE ENZYMES MONDEGO BIO, LDA. (PT) 2024-08-08 US claimed
EP-4408432-A1 MEDICAMENT COMPRISING A P2X4 RECEPTOR ANTAGONIST FOR PREVENTING OR TREATING NOCICEPTIVE PAIN AND/OR VISCERAL PAIN Nippon Chemiphar Co., Ltd. (JP) 2024-08-07 EP claimed
EP-4288412-A1 MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME Rappta Therapeutics Oy (FI) 2023-12-13 EP claimed
US-20230303509-A1 SULFONAMIDO DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS NIKANG THERAPEUTICS, INC. 2023-09-28 US claimed
CN-116470121-A Low-temperature-resistant lithium battery 广东嘉尚新能源科技有限公司 2023-07-21 CN claimed
US-20230143059-A1 GCN2 MODULATOR COMPOUNDS Alesta Therapeutics BV (NL) 2023-05-11 US claimed
CN-1438997-A Inhibitors of 11-beta-hydroxy steroid dehydrogenase type I BIOVITRUM AB (SE) 2003-08-27 CN claimed
EP-1301480-A1 1,3-DISUBSTITUTED AND 1,3,3-TRISUBSTITUTED PYRROLIDINES AS HISTAMINE-3 RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS ABBOTT LABORATORIES (US) 2003-04-16 EP claimed
WO-2002006223-A1 1,3-DISUBSTITUTED AND 1,3,3-TRISUBSTITUTED PYRROLIDINES AS HISTAMINE-3 RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS ABBOTT LABORATORIES (US) 2002-01-24 WO claimed
JP-2001527390-A 2001-12-25 JP claimed
CN-1269136-A Fluoric alkenyl compound and use as insect repellent agent MONSANTO CO (US) 2000-10-11 CN claimed
EP-1011655-A1 INHIBITORS OF LEADERLESS PROTEIN EXPORT Ciblex Corporation (US) 2000-06-28 EP claimed
WO-1998037880-A1 INHIBITORS OF LEADERLESS PROTEIN EXPORT CIBLEX CORPORATION (US) 1998-09-03 WO claimed
EP-0850218-A1 HERBICIDAL SULFONAMIDES E.I. DU PONT DE NEMOURS AND COMPANY (US) 1998-07-01 EP claimed
CN-1117291-A 4-Hydroxy-pyran-2-one derivatives for the treatment of retroviral infections UPJOHN CO (US) 1996-02-21 CN claimed
CN-1090279-A Be used for the treatment of HIV and other retroviral pyran-2-ones and 5,6-dihydropyrane-2-ketone UPJOHN CO (US) 1994-08-03 CN claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12630529-B2 GCN2 modulator compounds NR3C1, GCN1, EIF2AK4 GAA 3587/4885L3MBTL1 1704/4885CA1 3553/4885
US-20230303509-A1 SULFONAMIDO DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS CDK2, CCNK, CCNI GAA 1896/4885L3MBTL1 4315/4885CA1 3540/4885
US-20240262801-A1 COMPOUNDS HAVING 5-(2-FLUORO-6-HYDROXYPHENYL)-1,2,5-THIADIAZOLIDIN-3-ONE 1,1-DIOXIDE AS INHIBITORS OF PROTEIN KINASE PHOSPHATASE ENZYMES PPM1A, TH, PPM1G GAA 375/4885L3MBTL1 3583/4885CA1 2273/4885
US-20260022096-A1 NOVEL SULFONAMIDES AND THEIR USE AS NEUROPROTECTIVE AND/OR NEURORESTORATIVE AGENTS CNR1, CDR2, SMN1; SMN2 GAA 2022/4885L3MBTL1 3073/4885CA1 93/4885
US-20230143059-A1 GCN2 MODULATOR COMPOUNDS EIF2AK4, GPR119, GCN1 GAA 2129/4885L3MBTL1 2173/4885CA1 4675/4885
US-12331026-B2 Sulfonamido derivatives as cyclin-dependent kinase 2 inhibitors CDK2, CCNK, CCNI GAA 1896/4885L3MBTL1 4315/4885CA1 3540/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.